Provided by Tiger Trade Technology Pte. Ltd.

NovoCure

15.51
-0.1200-0.77%
Volume:342.60K
Turnover:5.34M
Market Cap:1.81B
PE:-11.86
High:16.07
Open:15.26
Low:15.10
Close:15.63
52wk High:21.45
52wk Low:9.82
Shares:116.45M
Float Shares:96.42M
Volume Ratio:1.36
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3082
EPS(LYR):-1.2221
ROE:-43.22%
ROA:-9.26%
PB:5.34
PE(LYR):-12.69

Loading ...

Novocure Director Timothy Scannell Retires from Board

Reuters
·
Yesterday

NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors

TIPRANKS
·
Sep 05

Novocure CEO to Speak at Wells Fargo Healthcare Conference

Reuters
·
Sep 02

Novocure Announces Upcoming Investor Events

THOMSON REUTERS
·
Sep 02

Oncology Firm Novocure Says Cyberattack Exposed US Patient Records

Reuters
·
Sep 01

Novocure aware of unauthorized access to some information systems

TIPRANKS
·
Sep 01

Novocure Limited: Do not Believe Incident Will Have Material Impact or Likely Material Impact on Financial Condition & Results of Operations

THOMSON REUTERS
·
Sep 01

Novocure - no Access to Medical Devices Obtained; Operations and Systems Fully Functional - SEC Filing

THOMSON REUTERS
·
Sep 01

Novocure - Reports Unauthorized Access to Information Systems in Mid-August 2026 - SEC Filing

THOMSON REUTERS
·
Sep 01

Novocure - Exposed Data Included Internal Patient ID Numbers for over 1,400 U.S. Records - SEC Filing

THOMSON REUTERS
·
Sep 01

Novocure - General Contact Information for Providers and Employees was Exposed - SEC Filing

THOMSON REUTERS
·
Sep 01

Novocure Investigates Unauthorized Access to Some Information Systems

Reuters
·
Sep 01

Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?

Simply Wall St.
·
Aug 30

Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?

Simply Wall St.
·
Aug 22

NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued

Simply Wall St.
·
Aug 11

NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years

Simply Wall St.
·
Jul 30

NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding

Benzinga Earnings
·
Jul 24

Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating

MT Newswires Live
·
Jul 24

Novocure price target raised to $20 from $18 at Wedbush

TIPRANKS
·
Jul 24

NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery

TradingKey
·
Jul 24